Skip to main content

Table 4 Treatment outcomes of patients with and without KDIGO 3 acute kidney injury, and with two different formulations of intravenous colistin

From: Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study

  KDIGO 3 AKI P-value Intravenous colistin  
Yes, n = 41 No, n = 154 Locolin®, n = 95 Colimycin®, n = 100
Ventilator days (Median, IQR) 36 (17–52) 22 (13–42) 0.036 28 (15–48) 24 (13–47) 0.048
ICU stay (days) (Median, IQR) 31 (19–47) 30 (20–51) 0.889 30 (19–47) 31 (21–54) 0.285
Hospital stay (days) (Median, IQR) 60 (38–94) 53 (31–80) 0.133 56 (35–87) 50 (29–76) 0.075
Mortality
Day 28 14 (34.1%) 62 (40.3%) 0.476 34 (35.8%) 42 (42%) 0.374
Discharge 28 (68.3%) 91 (59.1%) 0.283 56 (58.9%) 63 (63%) 0.562
  1. AKI acute kidney injury, ICU intensive care unit, IQR interquartile range